VKTXViking TherapeuticsVKTX info
$64.45info2.40%24h
Global rank2302
Market cap$6.08B
Change 7d2.86%
YTD Performance247.81%
SP500 benchmarkOutperform
P/E-70.82
P/S0
Revenue$0
Earnings-$85.89M
Dividend yield-
Main Sector
Healthcare

Viking Therapeutics (VKTX) Stock Overview

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

VKTX Stock Information

Symbol
VKTX
Address
9920 Pacific Heights BoulevardSan Diego, CA 92121United States
Founded
-
Trading hours
-
Website
https://www.vikingtherapeutics.com
Country
πŸ‡ΊπŸ‡Έ United States
Phone Number
858 704 4660

Viking Therapeutics (VKTX) Price Chart

-
Value:-

Viking Therapeutics Overview: Key Details and Summary

Stock data
2023
Change
Price
$64.45
N/A
Market Cap
$6.08B
N/A
Shares Outstanding
94.35M
22.79%
Employees
23.00
N/A
Valuation
2023
Change
P/E Ratio
-70.82
N/A
Earnings
2023
Change
Revenue
$0
N/A
Earnings
-$85.89M
N/A
EPS
-0.91
N/A
Earnings Yield
-0.0141
N/A
logo
Facebook Icon
Twitter Icon
Linkedin Icon
Β© 2024 Topstocks.org